Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary A…

Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approvedCAMBRIDGE, Mass ...
The Manila Times

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products. Bolsters and ...
Analytics Insight

How Companies Stay Competitive Through Continuous Innovation

In the high-stakes world of modern business, failure rarely happens overnight. Most companies don't lose because of one big ...